Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Increases By 109.7%

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the target of a large growth in short interest during the month of February. As of February 27th, there was short interest totaling 42,416 shares, a growth of 109.7% from the February 12th total of 20,230 shares. Approximately 6.2% of the company’s stock are short sold. Based on an average daily trading volume, of 248,360 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily trading volume, of 248,360 shares, the days-to-cover ratio is presently 0.2 days. Approximately 6.2% of the company’s stock are short sold.

Institutional Trading of Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC bought a new position in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned 14.71% of Biodexa Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.

Biodexa Pharmaceuticals Price Performance

Shares of Biodexa Pharmaceuticals stock traded down $0.02 during trading on Thursday, hitting $0.90. 17,320 shares of the stock traded hands, compared to its average volume of 300,237. The firm’s fifty day moving average is $1.63 and its 200-day moving average is $4.31. Biodexa Pharmaceuticals has a 52 week low of $0.87 and a 52 week high of $26.50.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BDRX. Wall Street Zen upgraded Biodexa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, February 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.